Spiegelmer

Spiegelmer (from the German Spiegel, meaning "mirror," and the Greek meros, meaning "part" or "oligomer") is a synthetic, mirror-image oligonucleotide aptamer—typically 35 to 50 nucleotides in length—constructed from non-natural β-L-ribonucleotides (L-RNA) or β-L-deoxyribonucleotides (L-DNA) rather than the biological β-D-nucleotides found in all terrestrial organisms. Because every stereocenter in the pentose sugar of an L-nucleotide (C1', C2', C3', and C4' in β-L-ribose) is inverted relative to natural β-D-ribose, an L-RNA oligomer is the three-dimensional topological enantiomer (non-superimposable mirror image) of a D-RNA oligomer of the identical nucleobase sequence, twisting into a left-handed A-form double helix instead of a right-handed helix.

Invented in 1996 by Sven Klussmann, Alexis Nolte, Rolf Bald, Volker A. Erdmann, and Jens P. Fürste (Nature Biotechnology) and developed for clinical pharmacology by NOXXON Pharma (now Aptarion Biotech), Spiegelmers unite the sub-nanomolar molecular recognition of conventional aptamers with metabolic stability in biological fluids. Because mammalian and microbial nucleases are homochiral enzymes built from L-amino acids whose active sites are stereochemically tailored to cleave right-handed D-sugar-phosphate backbones, L-oligonucleotide Spiegelmers resist enzymatic degradation in human plasma for more than 60 days and avoid activating innate immune nucleic-acid sensors.

Overcoming the Stereoselectivity of Biological Polymerases

A biochemical barrier initially prevented the direct in vitro selection of L-RNA aptamers: standard SELEX (Systematic Evolution of Ligands by Exponential Enrichment, where bound sequences amplify via an e^*k*t growth phase) relies on natural biological enzymes—such as T7 RNA polymerase, avian myeloblastosis virus reverse transcriptase, and Thermus aquaticus (Taq) DNA polymerase—to amplify winning sequences between selection rounds. Because the active sites of natural polymerases are homochiral, they cannot accept L-nucleoside triphosphates (L-NTPs or L-dNTPs) as substrates to replicate or transcribe L-nucleic acid templates.

Klussmann, Fürste, and colleagues solved this enzymatic bottleneck by applying Louis Pasteur's law of reciprocal chiral symmetry in a four-step mirror-image (chiral-inversion) SELEX protocol:

1. Chemical Synthesis of the Mirror-Image Target (D-Peptide / D-Protein): Using solid-phase peptide synthesis (Fmoc chemistry) and native chemical ligation with non-natural D-amino acids, chemists synthesize the enantiomer (D-protein or D-peptide) of the desired natural biological target (an L-protein such as a human chemokine or peptide hormone, or the opposite enantiomer of a chiral small molecule). When folded in aqueous buffer, the synthetic D-protein adopts the mirror-image tertiary structure of the natural L-protein.
2. Standard Enzymatic SELEX with a Natural D-RNA Library: A randomized library of 10¹⁴ to 10¹⁵ natural D-RNA (or D-DNA) sequences is incubated with the immobilized synthetic D-target. Because D-RNA can be reverse-transcribed and amplified by standard biological polymerases, 8 to 15 iterative rounds of selection and enzymatic amplification isolate high-affinity D-aptamers that bind the synthetic D-target with equilibrium dissociation constants (K_d) in the picomolar-to-nanomolar range.
3. Cloning and Sequencing: The winning D-aptamer clones are sequenced and truncated to their minimal 35-to-45-nt ligand-binding core.
4. Chemical Synthesis of the L-RNA Enantiomer (The Spiegelmer): Using automated solid-phase phosphoramidite synthesis with β-L-ribonucleoside phosphoramidites, the identical primary nucleotide sequence is synthesized as an L-RNA oligonucleotide. By reflection symmetry across a mirror plane, the left-handed L-RNA Spiegelmer binds the natural biological L-protein target with the same dissociation constant (K_d) and specificity with which the selected D-aptamer bound the synthetic D-protein.

Biostability, Immunological Silence, and Clinical Candidates

Unlike modified D-aptamers, which require 2'-fluoro or 2'-O-methyl substitutions that can alter RNA folding or release fluorinated nucleotide metabolites upon eventual catabolism, L-RNA Spiegelmers retain the native 2'-hydroxyl group on every ribose ring while remaining uncleaved in undiluted human serum at 37 °C for weeks. Moreover, because innate immune pattern-recognition receptors—including endosomal Toll-like receptors (TLR3, TLR7, TLR8, and TLR9) and cytosolic helicases (RIG-I)—are chiral L-proteins, Spiegelmers do not trigger interferon-α or pro-inflammatory cytokine cascades.

When conjugated at their 5'- or 3'-terminus to a 40-kDa branched polyethylene glycol (PEG) tail to slow renal glomerular filtration (yielding an in vivo plasma elimination half-life of 24 to 48 hours in humans), three Spiegelmers have advanced through Phase I/II human clinical trials:

1. Olaptesed pegol (NOX-A12): A 45-nt PEGylated L-RNA Spiegelmer that binds and neutralizes the chemokine CXCL12 (stromal cell-derived factor-1, SDF-1) with K_d = 200 pM, blocking CXCR4/CXCR7 signaling to mobilize leukemic cells and inhibit vasculogenesis in glioblastoma and pancreatic cancer.
2. Emapticap pegol (NOX-E36): A 40-nt PEGylated L-RNA Spiegelmer targeting the pro-inflammatory chemokine CCL2 (monocyte chemoattractant protein-1, MCP-1) (K_d = 1.3 nM) for diabetic nephropathy.
3. Lexaptepid pegol (NOX-H94): A 44-nt PEGylated L-RNA Spiegelmer that binds human hepcidin-25 (K_d = 0.65 nM) to restore ferroportin-mediated iron export in anemia of systemic inflammation.

Cross-Chiral Polymerase Ribozymes and Origin-of-Life Homochirality

In prebiotic chemistry and the RNA World, Spiegelmers illuminate the origin of biological homochirality—why terrestrial life uses D-RNA/D-DNA and L-proteins. In 1984, Gerald F. Joyce, George M. Visser, and Leslie E. Orgel demonstrated enantiomeric cross-inhibition: during non-enzymatic template-directed polymerization of D-RNA in a racemic prebiotic mixture containing both D- and L-activated mononucleotides, incorporation of a single mirror-image L-nucleotide at the 3'-primer terminus functions as a chain terminator that halts further elongation.

However, because a folded D-RNA aptamer or ribozyme can recognize an L-RNA substrate via tertiary structural contacts rather than antiparallel Watson–Crick base pairing (which fails between opposite chiralities due to sugar-pucker clash), Jonathan T. Sczepanski and Gerald F. Joyce (2014, Nature) evolved an 83-nucleotide cross-chiral RNA polymerase ribozyme. In this system, a right-handed D-RNA ribozyme binds a left-handed L-RNA template/primer duplex via tertiary interactions and polymerizes L-NTPs or L-oligonucleotide triplets to synthesize the full-length mirror-image L-RNA polymerase ribozyme (a catalytic Spiegelmer), which in turn synthesizes the D-RNA ribozyme—providing both a model for how early ribozymes operated in racemic prebiotic environments and an enzymatic route to amplify L-RNA Spiegelmers (complemented by synthetic D-amino acid T7 RNA polymerase synthesized by Ting Zhu and colleagues).

Why can blood nucleases not degrade a Spiegelmer?

All natural enzymes in the human body—including RNase A, DNase I, and serum phosphodiesterases—are built from L-amino acids. Because an enzyme's active site is a three-dimensional chiral pocket ("a left-handed glove"), it can only fit and cleave natural nucleic acids built from right-handed β-D-ribose or β-D-deoxyribose sugars. A Spiegelmer is synthesized from mirror-image β-L-ribose or β-L-deoxyribose nucleotides, twisting into a left-handed helix that cannot fit into the catalytic pocket of any biological nuclease, giving unmodified Spiegelmers a serum half-life exceeding 60 days.

How do scientists use natural polymerases to evolve L-RNA Spiegelmers if polymerases only work on D-RNA?

Natural polymerases (like T7 RNA polymerase and Taq polymerase) cannot copy L-RNA directly. To solve this, researchers exploit chiral reflection symmetry: first, they chemically synthesize the mirror-image D-amino acid version (D-protein) of the natural human L-protein target; second, they perform standard enzymatic SELEX using a normal D-RNA library and normal polymerases to find a D-RNA aptamer that binds the synthetic D-protein; third, they sequence that winning D-RNA and chemically synthesize the identical sequence out of L-ribonucleotides. By mirror symmetry, the resulting L-RNA Spiegelmer binds the natural L-protein with the same sub-nanomolar affinity.

How can a cross-chiral ribozyme copy an RNA strand of the opposite handedness?

A right-handed D-RNA strand and a left-handed L-RNA strand cannot form a stable Watson–Crick double helix with each other because their opposite ribose sugar puckers cause steric collisions along the backbone. In 2014, Jonathan Sczepanski and Gerald Joyce overcame this by evolving a cross-chiral RNA polymerase ribozyme: the D-RNA ribozyme does not base-pair with the L-RNA template; instead, it grips the sugar-phosphate backbone of an L-RNA primer–template duplex using tertiary structural contacts and catalyzes the addition of L-NTPs paired against the L-RNA template.

1. Klussmann, S., Nolte, A., Bald, R., Erdmann, V. A., & Fürste, J. P. (1996). "Mirror-image RNA that binds D-adenosine." Nature Biotechnology, 14(9), 1112–1115. https://doi.org/10.1038/nbt0996-1112
2. Nolte, A., Klussmann, S., Bald, R., Erdmann, V. A., & Fürste, J. P. (1996). "Mirror-design of L-oligonucleotide ligands binding to L-arginine." Nature Biotechnology, 14(9), 1116–1119. https://doi.org/10.1038/nbt0996-1116
3. Vater, A., & Klussmann, S. (2015). "Turning mirror-image oligonucleotides into drugs: The evolution of Spiegelmer therapeutics." Drug Discovery Today, 20(1), 147–155. https://doi.org/10.1016/j.drudis.2014.09.004
4. Sczepanski, J. T., & Joyce, G. F. (2014). "A cross-chiral RNA polymerase ribozyme." Nature, 515(7527), 440–442. https://doi.org/10.1038/nature13900